The company's compounds are used in Suzuki coupling reactions, in which molecules are joined together through the formation for bonds between carbon molecules. This type of reaction is extensively used in pharmaceutical industry.
Boron Molecular's non-executive director, David McAuliffe, noted that the company already generates in excess of 50 per cent of its organoboron compound revenue from the US, but plans to grow that even further by opening an office there.
Boron Molecular said anticipates the agency agreement will provide access to a greater number of customers in the company's largest market and it is expected that a presence in the US will further enhance the company's growing reputation in that territory as a provider of high quality, competitively priced organoboron products and services.
Boron Molecular Inc will officially commence operations on 27 September.